

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Certificate of Mailing: Date of Deposit: 3/19/04

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne

Printed name of person mailing correspondence

Colleen Coyne

Signature of person mailing correspondence

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Rima Rozen	Art Unit:	1634
Serial No.:	09/931,795	Examiner:	Carla J. Myers
Filed:	August 16, 2001	Customer No.:	21559
Title:	METHODS FOR SELECTING A THERAPY FOR A SUBJECT SUFFERING FROM SCHIZOPHRENIA (Amended)		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION OF DR. RIMA ROZEN UNDER 37 C.F.R. § 1.132**  
**TRAVERSING GROUNDS OF REJECTION**

Under 37 C.F.R. § 1.132, I declare:

1. I am the inventor of the subject matter described and claimed in the above-captioned patent application.
2. I have read the Office Action mailed on November 19, 2003.
3. Diseases (e.g., schizophrenia, premature vascular disease, and arterial and venous thrombotic phenomena) associated with an MTHFR mutation that reduces MTHFR enzyme activity or thermostability share a common defect in folate metabolism that increases plasma levels of homocysteine and contributes to

disease pathology. As disclosed in our specification, we have found that schizophrenia is correlated with an MTHFR C677T mutation, and that patients having this mutation typically have increased levels of homocysteine. Given these facts, it is reasonable to expect that methods that normalize levels of homocysteine, such as increasing plasma folate levels, would prevent or delay a schizophrenia associated with an MTHFR C677T mutation.

4. In addition, increasing folic acid levels prevents or delays diseases associated with high levels of homocysteine in individuals having any type of MTHFR mutation that reduces enzyme activity or thermostability.

5. Based on our results with drug responsiveness in patients carrying the heterozygous MTHFR C677T mutation, one skilled in the art would expect that patients carrying mutations that have similar effects on the biochemical characteristics of MTHFR would also share a similar responsiveness to a neuroleptic therapy.

6. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such

willful false statements may jeopardize the validity of the application or any patents issued thereon.

Date: Mar. 19/04

Rima Rozen  
Dr. Rima Rozen